DUNWOODY, Ga. — Three years ago, with the opioid epidemic taking off, police officers in this affluent Atlanta suburb noticed an uptick in overdoses. Sgt. Robert Parsons rushed to equip his fellow officers with a lifesaving tool: the opioid antidote naloxone.

He stumbled across a drug company that was donating free cartons of naloxone auto-injectors to police agencies, and placed an order online. Within months, he had revived a man. But the following spring, when another batch of naloxone arrived, he was surprised to find that the injectors were set to expire in four months.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy